Kolexia
Metges Jean-Philippe Gastro-entérologie
Metges Jean-Philippe
Gastro-entérologie
Hôpital Morvan
Brest, France
281 Activités
18.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Tumeurs de l'oesophage Carcinomes Tumeurs de l'estomac Tumeurs du pancréas Métastase tumorale Carcinome épidermoïde Tumeurs neuroendocrines

Collaborateurs

Voir plus
Tougeron David
Tougeron David
Hôpital La Miletrie, Poitiers, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Lecomte Thierry
Lecomte Thierry
Hôpital Trousseau Chambray lès Tours, Chambray-lès-Tours, France
Faroux Roger
Faroux Roger
Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France

Industries

Voir plus
MSD
24 collaboration(s)
Dernière en 2023
Sanofi
9 collaboration(s)
Dernière en 2021
CanceroDigest
9 collaboration(s)
Dernière en 2022
B3TSI
8 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MOUNTAINEER-03: An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Essai Clinique (Seagen)   15 mars 2024
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations: A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
Essai Clinique (Fore Biotherapeutics)   05 mars 2024
HERIZON-GEA-01: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Essai Clinique (Jazz Pharmaceuticals)   04 mars 2024
RePERSO: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
Essai Clinique (CHU Rennes)   30 janvier 2024
IMMUNO-BIL: Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Essai Clinique (AstraZeneca)   03 janvier 2024
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.
Journal of the National Comprehensive Cancer Network : JNCCN   16 décembre 2023
From early risk to one-year mortality: a comprehensive assessment of postoperative venous thromboembolism in upper gastrointestinal cancer patients - a nationwide cohort study.
International journal of surgery (London, England)   11 décembre 2023
130O The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Abstract Book of the ESMO Asia Congress 2023, 1-3 December 2023   01 novembre 2023
1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023